Market open
Vaxcyte/$PCVX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Ticker
$PCVX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
254
Website
Vaxcyte Metrics
BasicAdvanced
$11B
-
-$4.46
1.01
-
Price and volume
Market cap
$11B
Beta
1.01
52-week high
$116.95
52-week low
$58.10
Average daily volume
1.2M
Financial strength
Current ratio
17.884
Quick ratio
17.759
Long term debt to equity
0.536
Total debt to equity
0.818
Management effectiveness
Return on assets (TTM)
-14.93%
Return on equity (TTM)
-21.06%
Valuation
Price to book
3.26
Price to tangible book (TTM)
3.26
Price to free cash flow (TTM)
-16.558
Growth
Earnings per share change (TTM)
35.91%
3-year earnings per share growth (CAGR)
35.53%
What the Analysts think about Vaxcyte
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Vaxcyte Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vaxcyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vaxcyte News
AllArticlesVideos
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Seeking Alpha·2 weeks ago
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
GlobeNewsWire·1 month ago
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $11B as of January 27, 2025.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of January 27, 2025.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of January 27, 2025.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.